Literature DB >> 9407432

Mechanisms of progression in autosomal dominant polycystic kidney disease.

J J Grantham1.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) progresses to end-stage renal insufficiency before the age of 73 in approximately 48% of affected individuals. Why the disease, characterized by innumerable cysts arising in proximal and distal tubules, eliminates functioning non-cystic parenchyma in some patients and spares other is a mystery. The cysts initiate in early childhood in fewer than 1% of renal tubules as a consequence of the focal expression of mutated DNA. Tubule cells proliferate, causing segmental dilation, in association with the abnormal deposition of extracellular matrix proteins. Most of the cysts separate from the parent tubules and fill with fluid by cAMP-mediated chloride secretion. Risk factors associated with accelerated loss of renal function include: genotype (PKD Type 1 progresses more rapidly than PKD Type 2); gender (males progress more rapidly than females); race (black patients progress more rapidly than whites); hypertension; proteinuria. The relation between kidney size and progression to renal failure is debated. Progressive PKD is associated with the cellular expression of proto-oncogenes (fos, myc, ras, erb), growth factors (EGF, HGF, acid and basic FGF), chemokines (MCP-1. osteopontin), metalloproteinases, and apoptotic markers, and the interstitial accumulation of Types I and IV collagen, laminin, fibronectin, macrophages and fibroblasts, the magnitudes of which increase with age. Cyst activating factor (CAF), a neutral lipid identified in cyst fluid that stimulates fluid secretion and proliferation of renal epithelial cells and monocyte chemotaxis, has recently been identified as a potential progression factor. In those patients destined to develop renal failure there is loss of non-cystic parenchyma in association with mass replacement by fluid-filled cysts in a network of interstitial fibrosis. The decline in renal function is probably the consequence of processes leading to interstitial fibrosis, as in other nephropathies, rather than due to simple mechanical displacement of parenchyma by cysts.

Entities:  

Mesh:

Year:  1997        PMID: 9407432

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  26 in total

1.  Exocyst is involved in cystogenesis and tubulogenesis and acts by modulating synthesis and delivery of basolateral plasma membrane and secretory proteins.

Authors:  J H Lipschutz; W Guo; L E O'Brien; Y H Nguyen; P Novick; K E Mostov
Journal:  Mol Biol Cell       Date:  2000-12       Impact factor: 4.138

2.  Do mTOR inhibitors still have a future in ADPKD?

Authors:  Norberto Perico; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2010-12       Impact factor: 28.314

3.  Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.

Authors:  Tamio Yamaguchi; Gail A Reif; James P Calvet; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

4.  Endothelial dysfunction and oxidative stress in polycystic kidney disease.

Authors:  Jelena Klawitter; Berenice Y Reed-Gitomer; Kim McFann; Alexander Pennington; Jost Klawitter; Kaleab Z Abebe; Jacek Klepacki; Melissa A Cadnapaphornchai; Godela Brosnahan; Michel Chonchol; Uwe Christians; Robert W Schrier
Journal:  Am J Physiol Renal Physiol       Date:  2014-09-18

5.  Effect of statin therapy on disease progression in pediatric ADPKD: design and baseline characteristics of participants.

Authors:  Melissa A Cadnapaphornchai; Diana M George; Amirali Masoumi; Kim McFann; John D Strain; Robert W Schrier
Journal:  Contemp Clin Trials       Date:  2011-01-23       Impact factor: 2.226

6.  Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

Authors:  Ayumi Takakura; Erik A Nelson; Nadeem Haque; Benjamin D Humphreys; Kambiz Zandi-Nejad; David A Frank; Jing Zhou
Journal:  Hum Mol Genet       Date:  2011-08-05       Impact factor: 6.150

Review 7.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

8.  Intermediate volume on computed tomography imaging defines a fibrotic compartment that predicts glomerular filtration rate decline in autosomal dominant polycystic kidney disease patients.

Authors:  Anna Caroli; Luca Antiga; Sara Conti; Aurelio Sonzogni; Giorgio Fasolini; Patrizia Ondei; Norberto Perico; Giuseppe Remuzzi; Andrea Remuzzi
Journal:  Am J Pathol       Date:  2011-06-17       Impact factor: 4.307

Review 9.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

Review 10.  Polycystic kidney diseases: from molecular discoveries to targeted therapeutic strategies.

Authors:  O Ibraghimov-Beskrovnaya; N Bukanov
Journal:  Cell Mol Life Sci       Date:  2008-02       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.